<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01233349</url>
  </required_header>
  <id_info>
    <org_study_id>INQ/K/00310</org_study_id>
    <nct_id>NCT01233349</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Litramine in Overweight and Obese Subjects</brief_title>
  <official_title>Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate Safety and Efficacy of LitramineTM in Reducing Body Weight in Overweight and Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InQpharm Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InQpharm Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preparations that bind to nutritional fat and inhibit its absorption could be decisively&#xD;
      meaningful for the regulation of bodyweight or obesity. Further, it is known that soluble&#xD;
      fibres gel and swell in the stomach and thereby induce a feeling of satiety or fullness after&#xD;
      eating. Such effects are supposed to facilitate adherence to energy-restricted diets. The&#xD;
      medical device to be investigated contains a patented formula of fibre complex having a high&#xD;
      ability to bind to dietary fat.&#xD;
&#xD;
      Therefore, the rationale for this study is to confirm that Litramine's proven fat binding&#xD;
      capacity to increase fat excretion and modulate the feeling of satiety will translate into&#xD;
      measurable reduction in body weight. A double blind, randomized, placebocontrolled design has&#xD;
      been chosen to assess the efficacy and safety of Litramine in overweight and obese subjects&#xD;
      on a energy-restricted diet.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>weight loss (kg)</measure>
    <time_frame>after 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>body fat content and fat free mass</measure>
    <time_frame>after 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemogram, clinical chemistry parameter, and lipid profile</measure>
    <time_frame>after 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who lost at least 5% and 10% of baseline body weight</measure>
    <time_frame>after 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects global feeling of satiety</measure>
    <time_frame>every 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global evaluation of the incidence of food cravings</measure>
    <time_frame>every 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in waist circumference (cm)</measure>
    <time_frame>every 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>every 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>every 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat-soluble vitamins (A, D, E) and electrolytes (calcium, magnesium, sodium, potassium)</measure>
    <time_frame>after 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global evaluation of safety/tolerability</measure>
    <time_frame>after 12 weeks</time_frame>
    <description>by subjects and investigators - based on rating scales</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <condition>Weight Loss</condition>
  <arm_group>
    <arm_group_label>Litramine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Litramine</intervention_name>
    <description>2 tablets 3 times daily (oral consumption, 30 minutes after meal)</description>
    <arm_group_label>Litramine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 tablets 3 times daily (oral consumption, 30 minutes after meal)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  25 ≤ BMI ≤ 35&#xD;
&#xD;
          -  Expressed desire for weight loss&#xD;
&#xD;
          -  Accustomed to 3 main meals/day&#xD;
&#xD;
          -  Consistent and stable body weight 3 months prior to study enrolment&#xD;
&#xD;
          -  Commitment to avoid the use of other weight loss products during study&#xD;
&#xD;
          -  Commitment to adhere to diet recommendation&#xD;
&#xD;
          -  Females' agreement to use appropriate birth control methods during the active study&#xD;
             period&#xD;
&#xD;
          -  Subject declares in writing his/her consent to participate, understands requirements&#xD;
             of the study and is willing to comply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known sensitivity to the ingredients of the device&#xD;
&#xD;
          -  Presence of any active gastrointestinal disease&#xD;
&#xD;
          -  Malabsorption disorders (e.g. Coeliac disease)&#xD;
&#xD;
          -  Pancreatitis&#xD;
&#xD;
          -  Stenosis in the GI tract&#xD;
&#xD;
          -  Bariatric surgery&#xD;
&#xD;
          -  Abdominal surgery within the last 6 months prior to the study&#xD;
&#xD;
          -  History of eating disorders like bulimia, anorexia nervosa&#xD;
&#xD;
          -  History of renal disease&#xD;
&#xD;
          -  History of nephrolithiasis&#xD;
&#xD;
          -  History of cardiac diseases&#xD;
&#xD;
          -  Osteoporosis&#xD;
&#xD;
          -  Other serious organ or systemic diseases such as cancer, HIV, or diabetes mellitus&#xD;
&#xD;
          -  Any medication that could influence GI functions such as antibiotics, laxatives,&#xD;
             opioids, anticholinergics, or anti-diarrheals (must have stopped 3 months before study&#xD;
             start)&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
&#xD;
          -  Any medication or use of products for the treatment of obesity (e.g., Orlistat, other&#xD;
             fatbinder, fatburner, satiety products etc.)&#xD;
&#xD;
          -  More than 3 hours serious sport activity per week&#xD;
&#xD;
          -  History of abuse of drugs, alcohol or medication&#xD;
&#xD;
          -  Smoking cessation within the 6 months prior to this study&#xD;
&#xD;
          -  Inability to comply due to language difficulties&#xD;
&#xD;
          -  Participation in similar studies or weight loss programs within the 6 months prior to&#xD;
             this study&#xD;
&#xD;
          -  Participation in other studies within the last 4 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Grube, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Grube</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2010</study_first_posted>
  <last_update_submitted>October 12, 2011</last_update_submitted>
  <last_update_submitted_qc>October 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>overweight</keyword>
  <keyword>obesity</keyword>
  <keyword>weight loss</keyword>
  <keyword>body fat</keyword>
  <keyword>waist circumference</keyword>
  <keyword>satiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

